JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Table 1

Demographic and clinical features of HD and RRMS patients.

	HD	RRMS patients
		0	12	24	36
	15	19	29	32	12	6
F/M	7/8	7/12	13/17	17/14	8/4	2/4
Median age in years [IQR]	30	29.5	46.5	40	38	40.5
Median years of disease [IQR]	-	7.5	11.5	14	9	7
Median [IQR]	-	2	1	2.5	1	1
No (/N)	-	4/19	6/29	8/32	4/12	4/6
Interferon (/N)	-	13/19	20/29	19/32	7/12	2/6
Mitoxantrone and interferon (/N)	-	1/19	1/29	1/32	0/12	0/6
Glatiramer (/N)	-	1/19	2/29	4/32	1/12	0/6

HD: healthy donors, 0: 0 infusions, 12: from 1 to 12 infusions, 24: from 13 to 24 infusions, 36: from 25 to 36 infusions, and : over 36 infusions of natalizumab. : total number of patients; F: female; M: male; IQR: interquartile range; EDSS: Expanded Disability Status Scale, with values ranging from 0 (normal neurological examination) to 10 (bedridden patient) (1); therapy before starting natalizumab.